We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04250545
Recruitment Status : Suspended (Other - Pending amendment to update dose levels)
First Posted : January 31, 2020
Last Update Posted : October 4, 2022
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : September 30, 2023
Estimated Study Completion Date : September 30, 2023